On August 2, 2021 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in upcoming investor conferences in August (Press release, Selecta Biosciences, AUG 2, 2021, View Source [SID1234585512]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the panel can be found below.
BTIG Virtual Biotechnology Conference 2021
Format: Fireside chat and one-on-one investor meetings
Date: Monday, August 9, 2021
Presentation Time: 3:00 p.m. EDT
Canaccord Genuity 41st Annual Growth Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, August 11, 2021
Presentation Time: 9:30 a.m. EDT
Webcast: Click Here
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative. An archived webcast of the Canaccord corporate update will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.